Genetic Alliance, enGenome expand genomic interpretation access for rare disease labs

Genetic Alliance and enGenome are partnering to give more laboratories access to AI-guided genomic interpretation through the global rare disease genomics program. The move is meant to help diagnostic sites deliver faster, more standardized clinical-grade variant analysis for patients seeking answers.

Why it matters: - The partnership gives participating rare disease laboratories access to tools that can speed up and standardize genomic variant interpretation. - The collaboration is designed to support more equitable access to clinical genomic diagnostics across Genetic Alliance’s international network. - The effort could help more undiagnosed patients and families get answers faster.

What happened: - Genetic Alliance and enGenome announced a collaboration to expand access to advanced genomic interpretation in Genetic Alliance’s global rare disease genomics program. - enGenome will provide in-kind access to eVai, its AI-guided genomic interpretation platform. - The partnership was announced in Damascus, Maryland, on August 6, 2026. - Dubai Health, the network’s first laboratory partner in the Middle East, helped launch the collaboration after identifying a broader use case for enGenome’s platform across RISE participating labs. - Dubai Health was already using eVai in its own clinical genomics workflow and introduced Genetic Alliance to enGenome.

The details: - eVai rapidly classifies and prioritizes human genomic variants. - The platform is intended to support diagnostic laboratories with efficient and standardized clinical-grade genomic interpretation. - Genetic Alliance said network partners contribute more than testing capacity and also share technologies, platforms and workflows that can strengthen the broader program. - enGenome’s contribution is framed as part of the shared infrastructure needed to expand access to genomic diagnostics. - Genetic Alliance’s network now includes 26 clinical sites, nine laboratories and two software companies across 19 countries. - Genetic Alliance provides clinical genomic testing at no cost to undiagnosed children in under-resourced communities in the United States and low- and middle-income countries. - Genetic Alliance connects families with results, care, support, research opportunities and potential therapies through its international network. - enGenome is an Italian bioinformatics company with about a decade in the market. - eVai is a secure, CE-IVDR certified platform that supports automated variant classification, phenotype-driven prioritization and clinical reporting. - eVai is built to clinical-grade standards and is compliant with ISO, HIPAA and GDPR requirements. - enGenome also offers VarChat, an open-access GenAI assistant for genomic variants that retrieves scientific literature and condenses it into brief summaries. - More information is available on Genetic Alliance and enGenome. - Genetic Alliance also shared its LinkedIn page.

Between the lines: - The collaboration shows how a member of the network can contribute technology, not just test volume, to improve the broader system. - Dubai Health’s role suggests the network is using existing clinical workflows to surface tools that can be shared across sites. - The addition of software support may matter as rare disease programs scale and need more consistent interpretation across countries and laboratories. - Genetic Alliance and enGenome both cast the partnership as a way to widen equitable access, but the immediate operational value is likely in reducing friction for labs that need standardized variant analysis.

What’s next: - Genetic Alliance expects the enGenome partnership to support laboratories across its global network. - enGenome plans to support Dubai Health’s participation in the program and introduce eVai to Dubai Health’s international community of genomic laboratories. - The companies said the collaboration should help demonstrate how genomic interpretation technology can fit clinical workflows and support broader access worldwide.

The bottom line: - The deal turns genomic interpretation software into shared infrastructure for a rare disease network that spans 19 countries.